Im Fokus: Bronchialkarzinome - NSCLC und SCLC
Upfront Immunotherapy in metastatic Non-Small-Cell Lung Cancer
Frontline Treatment of Non-Oncogene Addicted Tumors in Review
The programmed death-1/programmed death ligand-1 immune-checkpoint inhibitors (PD-1/PD-L1) both as single agents or in combination with chemotherapy, anti–cytotoxic T-lymphocyte antigen 4 antibody (CTLA-4), or angiogenic therapy, have reshaped the metastatic non-small cell lung cancer frontline treatment landscape. This article aims to review first line therapy in of non-oncogene addicted metastatic non-small-cell lung cancer.